Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 18

1.

Priority Areas for National Action: Transforming Health Care Quality.

Institute of Medicine (US) Committee on Identifying Priority Areas for Quality Improvement; Adams K, Corrigan JM, editors.

Washington (DC): National Academies Press (US); 2003.

2.

Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient-controlled analgesia.

Overdyk FJ, Carter R, Maddox RR, Callura J, Herrin AE, Henriquez C.

Anesth Analg. 2007 Aug;105(2):412-8.

PMID:
17646499
3.

Clinical experience with patient-controlled analgesia using continuous respiratory monitoring and a smart infusion system.

Maddox RR, Williams CK, Oglesby H, Butler B, Colclasure B.

Am J Health Syst Pharm. 2006 Jan 15;63(2):157-64. No abstract available.

PMID:
16390930
4.

Variability in intravenous medication practices: implications for medication safety.

Bates DW, Vanderveen T, Seger D, Yamaga C, Rothschild J.

Jt Comm J Qual Patient Saf. 2005 Apr;31(4):203-10.

PMID:
15913127
5.
6.

Implementation of an i.v. medication safety system.

Williams CK, Maddox RR.

Am J Health Syst Pharm. 2005 Mar 1;62(5):530-6. No abstract available.

PMID:
15745919
7.

An intravenous medication safety system: preventing high-risk medication errors at the point of care.

Hatcher I, Sullivan M, Hutchinson J, Thurman S, Gaffney FA.

J Nurs Adm. 2004 Oct;34(10):437-9.

PMID:
15577664
8.

Preventing medication errors with smart infusion technology.

Wilson K, Sullivan M.

Am J Health Syst Pharm. 2004 Jan 15;61(2):177-83.

PMID:
14750402
9.

Findings from the ISMP Medication Safety Self-Assessment for hospitals.

Smetzer JL, Vaida AJ, Cohen MR, Tranum D, Pittman MA, Armstrong CW.

Jt Comm J Qual Saf. 2003 Nov;29(11):586-97.

PMID:
14619351
10.

An observational study of intravenous medication errors in the United Kingdom and in Germany.

Wirtz V, Taxis K, Barber ND.

Pharm World Sci. 2003 Jun;25(3):104-11.

PMID:
12840963
11.
12.

Medication errors and adverse drug events in pediatric inpatients.

Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, Goldmann DA.

JAMA. 2001 Apr 25;285(16):2114-20.

PMID:
11311101
13.
14.

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.

Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL.

JAMA. 1997 Jan 22-29;277(4):307-11.

PMID:
9002493
15.

In-hospital cardiopulmonary resuscitation: a 30-year review.

Schneider AP 2nd, Nelson DJ, Brown DD.

J Am Board Fam Pract. 1993 Mar-Apr;6(2):91-101.

PMID:
8452077
16.

Systems analysis of adverse drug events. ADE Prevention Study Group.

Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, Hallisey R, Ives J, Laird N, Laffel G, et al.

JAMA. 1995 Jul 5;274(1):35-43.

PMID:
7791256
17.

Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.

Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al.

JAMA. 1995 Jul 5;274(1):29-34.

PMID:
7791255
18.

The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II.

Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H.

N Engl J Med. 1991 Feb 7;324(6):377-84.

Supplemental Content

Support Center